Hatoon M. Ezzat

Contact InformationHematology-Hatoon Ezzat.jpg

490-1144 Burrard Street,
Vancouver, V6Z 2A5
Phone: (604) 684-5794
Email: hezzat@providencehematology.com

Current Positions

  • Head, Division of Hematology, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada.
  • Locum Hematologist (Champion of inherited blood disorders), Ministry of Health, Saudi Arabia.
  • Clinical Associate Professor of Hematology, University of British Columbia, Vancouver, Canada.
  • Medical director of Hemoglobinopathy program of BC, Providence Health Care, St. Paul’s Hospital, Vancouver, Canada.
  • Medical director of Hemosiderosis and Iron chelation program of BC, Providence Health Care, St. Paul’s Hospital, Vancouver, Canada.
  • Clinical Hematologist, Providence Hematology, Providence Hematology, St. Paul’s Hospital, Vancouver, Canada.

Research Interests

  • Hematologic Malignancies, Lymphoproliferative Malignancies, Hematological disorders in Immundeficiency and HIV infection.
  • Thalassaemia and other thalassemic syndromes.
  • Sickle cell diseases.
  • Iron overload and iron chelation.
  • Myelodysplastic Syndrome/Multiple Myeloma.

Publications

  1. Ezzat L, Ezzat H. The Effect of Anti Nuclear Antibody Positivity on Immune Thrombocytopenic Purpura and Its Clinical Clourse. Accepted and for publication March 30, 2017 to Hematology, Blood Transfusion & Disorders.
  2. Ou G, Ko H, Takach O, Sandhu N, Ezzat H. Utility of transient elastography (fibroscan) in estimating hepatic iron concentration in comparison to MRI in patients with transfusion dependent hemoglobinopathies, Journal Hemoglobin, International journal of Hemoglobin research, Vol. 41, 2017- Issue 1,http://dx.doi.org/10.1080/03630269.2017.1307763.
  3. Ezzat H, Wu J, Leitch H. Vitamin D Deficiency and Liver Iron Concentration Transfusion Dependent Hemoglobinopathies in British Columbia. Open Journal of Hematology, ISSN: 2075-907X, Vol. 6, 2015.
  4. Ezzat H, Schellenberg R, Leitch H, Vickars L. Successful Tolerance of Deserasirox Following Desensitization for Significant Skin Rash. Submitted to Hematologica 2012.
  5. Ezzat H, Cheung MC, Hicks LK, Murphy KC, Léger CS, Taggart LR, Boro J, Montaner JSG, Harris M, Vickars LM & Leitch HA. Incidence, Predictors and Significance of Severe Toxicity in Patients with HIV-Associated Hodgkin Lymphoma. Leuk Lymphoma. 2012 Jun 18 [Epub ahead of print].
  6. Rodrigo J, Hicks L, Cheung M, Song K, Ezzat H, Leger C, and Leitch H. HIV- Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Advances in Hematology. 2012;2012:735392. Epub 2011 Nov 14.
  7. Leitch H, Chase J, Goodman T, Ezzat H, Rollins M, Wong D, Badawi M, Leger CS, Ramadan KM, Barnett M, Foltz L, Vickars L. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010 Mar;28(1):40-8.
  8. Leitch HA, Ezzat H, Rollins MD, Goodman TA, Leger CS, Wong DHC, Ramadan KM, Foltz LM, Vickars LM. “Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy”. Blood; 112(11):617a, 2008.
  9. Ezzat H, Filipenko D, Vickars L, Galbraith P, Li C, Murphy K, Montaner J, Harris M, Hogg R, Vercauteren S, Leger CS, Zypchen L, Leitch HA. “Improved survival in HIV- Associated B-cell non-Hodgkin’s lymphoma with the addition of rituximab to chemotherapy in patients receiving Highly Active Anti-Retroviral Therapy.” HIV Clinical Trials 8(3):132-44, 2007.
  10. Ezzat H, Wong JC, Filipenko D, Vickars LM, Galbraith PF, Li CH, Murphy K, Montaner JSG, Harris M, Hogg RS, Vercauteren S, Leger CS, Zypchen L, Leitch HA “Improvement in Outcome of Patients with CD30+ HIV-Related Systemic B-Cell Non- Hodgkin’s Lymphoma (NHL) Providing HIV Infection is Adequately Controlled” Blood 108: 248b, 2006.

Education

  • Physician Leadership Program (PLP) diploma, Sauder’s School of Business, University of British Columbia, Vancouver, Canada (2019-present).
  • Master (MSc) of Science in Hemoglobinopathy, University College of London, London, UK (2010-2012).
  • Hematological Diseases in HIV/AIDS Population research fellowship, University of British Columbia, Vancouver, Canada (2008-2009).
  • Diploma in Medical Statistics, University of British Columbia, Vancouver, Canada (2008).
  • (FRCPC) Adult Clinical Hematology and bone marrow transplant Fellowship, University of British Columbia, Vancouver, Canada (2006-2008).
  • (ABIM) Adult Clinical Hematology and bone marrow transplant Fellowship, University of British Columbia, Vancouver, Canada (2006-2008).
  • (FRCPC) Internal Medicine Residency Program, University of British Columbia, Vancouver, Canada (2003-2006).
  • (ABIM) Internal Medicine Residency Program, University of British Columbia, Vancouver, Canada (2003-2006).
  • Internal Medicine Residency Program, King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia (1998-2001).
  • Internal Medicine Residency program, King Faisal Specialist Hospital &Research Center, Riyadh, Saudi Arabia (1996-1998).
  • Internship Certification, King Abdul-Aziz University Hospital, Jeddah, Saudi Arabia (1995-1996).
  • Bachelor of Medicine & Surgery, King Abdul-Aziz University, Jeddah, Saudi Arabia (1989-1995).